Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2007
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi). The company has no commercial product sales and relies on strategic alliances (Novartis, Merck, Biogen Idec) and government contracts (NIH) for revenue. Its lead program, ALN-RSV01 for respiratory syncytial virus (RSV), is in Phase I clinical trials.
Key Financial Metrics
| Metric (in thousands) | Q1 2007 | Q1 2006 |
|---|---|---|
| Net Revenues | $7,217 | $5,717 |
| Operating Expenses | $31,211 | $15,514 |
| Loss from Operations | $(23,994) | $(9,797) |
| Net Loss | $(21,645) | $(8,860) |
| Net Loss Per Share (Basic/Diluted) | $(0.58) | $(0.30) |
| Cash and Cash Equivalents (End of Period) | $66,662 | $56,804 |
| Marketable Securities | $137,804 | $89,305 |
| Total Liquidity (Cash + Securities) | $204,466 | $146,109 |
| Notes Payable (Total) | $8,360 | $9,136 |
| Accumulated Deficit | $(162,171) | $(140,527) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 26% to $7.2 million, driven by new collaborations with Biogen Idec and the NIH (Ebola program), partially offset by a decrease in Novartis revenue due to reduced resource allocation.
- Expense Surge: Operating expenses more than doubled to $31.2 million. Research and Development (R&D) expenses rose 128% to $26.7 million. This was primarily due to a $7.9 million non-cash license fee and $0.4 million cash payment to Tekmira Pharmaceuticals for liposomal delivery technology, alongside increased clinical trial costs for RSV.
- Cash Flow: Net cash used in operating activities increased to $11.0 million (from $8.7 million). Net cash used in investing activities spiked to $49.9 million due to net purchases of marketable securities ($48.5 million).
- Financing: Unlike Q1 2006, which saw $62.5 million in financing proceeds from a public offering, Q1 2007 saw a net cash use of $0.4 million in financing activities.
Outlook, Risks, and Management Commentary
- Liquidity Position: Management believes existing resources ($204.5 million in cash and marketable securities) combined with expected collaboration funding are sufficient to fund operations for at least the next several years.
- Strategic Alliances: Revenue is heavily dependent on alliances with Novartis, Merck, and Biogen Idec. The Novartis agreement includes an "Integration Option" allowing Novartis to integrate Alnylam's IP, potentially making them a competitor.
- Development Pipeline: The company is advancing ALN-RSV01 (RSV) and has pre-clinical programs for influenza, hypercholesterolemia, liver cancer, and Ebola. No products are expected to generate sales revenue in the foreseeable future.
- Risks:
- Technology Risk: RNAi is an unproven therapeutic approach; no siRNA-based drugs have received regulatory approval.
- Capital Needs: The company expects to incur significant losses for several years and may require additional equity or debt financing, which could dilute shareholders.
- Patent Litigation: The company faces potential opposition to key patents (Kreutzer-Limmer) in Europe and Australia, which could impact exclusivity.
- Manufacturing: Limited internal manufacturing capabilities require reliance on third-party contract manufacturers.
Investor Verification Checklist
- Non-Cash Expenses: Verify the impact of the $7.9 million non-cash license fee to Tekmira on R&D expenses and cash flow reconciliation.
- Revenue Recognition: Review the proportional performance method used for recognizing deferred revenue from Novartis and other collaborators.
- Patent Status: Monitor the outcome of opposition proceedings regarding the Kreutzer-Limmer patents in the EPO and Australia.
- Cash Burn Rate: Assess the sustainability of the current cash burn rate against the $204.5 million liquidity position given the lack of product sales.
- Collaboration Terms: Evaluate the terms of the Novartis "Integration Option" and the potential for Novartis to become a direct competitor.